BIA responds to the announcement that UK Cabinet has approved the draft Brexit deal

In response to the announcement that UK Cabinet has approved the draft Brexit deal, BIA CEO, Steve Bates, said: "We welcome this week's progress on Brexit discussions with the initial agreement between the EU and UK on a withdrawal agreement and the political agreement on the outline of a future relationship. The BIA will now monitor and inform its members of the political debate that will ensue in the finely balanced UK parliament. There is significant detail to digest and we are engaging with members and others to understand the implications of the deal for the life sciences sector, and plan to produce a detailed briefing on this next week.

BIA heads to Hong Kong and China to explore future collaboration on weekend new US regulations on biotech investment come into force

The UK Bioindustry Association (BIA) is taking a delegation of members to China for BioCentury China Healthcare Summit to promote UK science to Chinese companies and investors to encourage further collaboration between the UK and China, and will be visiting Hong Kong to explore opportunities on their stock market.

BIA given permission to intervene in Actavis vs ICOS Supreme Court case

The UK BioIndustry Association (BIA) has been granted permission by the UK Supreme Court to intervene in a case that could have far-reaching impacts on the life sciences sector. The BIA is arguing that medical innovations should be patentable irrespective of how the invention is made.

BIA and ABPI input to MHRA consultation on EU Exit no deal contingency legislation for the regulation of medicines and medical devices

The UK BioIndustry Association (BIA) and the Association of the British Pharmaceutical Industry (ABPI) have submitted a joint submission in response to the MHRA and DHSC consultation on no deal contingency legislation for medicines and devices regulation for the UK.

Synpromics named among the top 50 fastest growing technology companies in the UK

Synpromics 12th in the Deloitte UK Technology Fast 50. Synpromics is delighted to announce that it has been ranked 12th in the Deloitte ‘UK Technology Fast 50’ at the annual awards ceremony in London last night.

Expedeon AG signs supply and license agreement with Quanterix Corporation for access to proprietary immunoassay technology

Expedeon’s proprietary immunoassay technology to be incorporated into Quanterix’ Simoa Planar Immunoassay products

Research Showcase launches new collaboration to accelerate translation of more predictive research models in drug discovery

Medicines Discovery Catapult and the National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs) announce strategic collaboration to accelerate the translation of more predictive in vitro research models into new products and services

New collaboration will advance human-based drug evaluation

Medicines Discovery Catapult and the Medical Research Council (MRC) Centre for Drug Safety Science (CDSS) at the University of Liverpool announce strategic collaboration to develop next generation human cell models

Event Feature: Window on Wuhan

World antibiotic awareness week

“Antimicrobial resistance is a real and current threat” – this was the warning we heard from David Roblin of Summit therapeutics in our recent interview for our Celebrating UK bioscience series. Antimicrobial resistance affects every nation on earth, and it’s getting worse. Much like the problem of climate change, the effects have been growing steadily and the problem does not respect boundaries. Infections arising from antimicrobial resistant microbes poses one of the greatest threats to modern medicine.

Professor Alvin Nienow wins Peter Dunnill award and the Advanced Therapies Manufacturing Taskforce wins Richard Wilson Impact award at bioProcessUK

The winner of this year’s Peter Dunnill Award to be presented at the bioProcessUK conference has been announced as Professor Alvin Nienow. Alvin is Emeritus Professor of Biochemical Engineering at the University of Birmingham, a Visiting Professor at Aston and Loughborough  Universities and a Fellow of the Royal Academy of Engineering. In addition to this the Advanced Therapies Manufacturing Taskforce has been announced as the winner of the Richard Wilson Impact award. 

CEO Update | Monday 12 November 2018

This week I am in China with a number of BIA members. This trip is the centrepiece of the BIA’s ramp up of engagement East in 2018. Building on our China Special Interest Group we are seeking to increase the number of UK biotech companies collaborating with, generating revenue from, and receiving investment from the Chinese market. In Hong Kong I am exploring how we can jointly build the life science analytical capability needed for global liquidity - and make dual listing - or similar - a practical reality for UK companies seeking investment there.